Exosome isolation manufacturing and characterization
New service to reliably and reproducibly isolate exosomes from almost any biofluid.
Amsbi has announced an exosome isolation, manufacturing and characterization service to enable R&D groups to accelerate their discovery and development activities.
Exosomes are small membrane vesicles with a size ranging from 40 to 100 nm. They are known to serve as functional mediators in cell interaction leading to cancer metastasis and have also been implicated in neurodegenerative diseases. Metastasis is a complex multistep process of cancer cell invasion, survival in blood vessels, attachment to and colonization of the host organ. Exosomes influence every step of this cascade and therefore represent a novel strategy for cancer therapy.
Drawing upon many years’ experience of working with exosomes, Amsbio is able to reliably and reproducibly isolate exosomes from almost any biofluid including plasma and tissue culture media, cerebrospinal fluid, synovial fluid, and even challenging fluids such as mouse bronchial alveolar fluid.
The new service enables labs to simply provide Amsbio with a biofluid and in return receive high-quality, functional exosomes that are ready to use. Backed by expert scientific support, the Amsbio exosome isolation and manufacturing service is available across a range of production scales to suit research needs now and development needs in future.
All exosomes supplied by Amsbio come complete with Nanoparticle Tracking Analysis (NTA) characterization data. NTA characterization data provides a clearer picture of the quality of your exosomes without needing to invest in your own NTA instrument. A typical NTA report includes particle analysis data on your exosome including the mean and mode diameter size, particle concentration, and video of the collected data, all gathered in triplicate. This service can also be offered on exosome samples prepared in your own lab.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...